TD Asset Management Inc Purchases 2,400 Shares of USANA Health Sciences, Inc. (NYSE:USNA)

TD Asset Management Inc lifted its position in USANA Health Sciences, Inc. (NYSE:USNA) by 26.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,500 shares of the company’s stock after purchasing an additional 2,400 shares during the quarter. TD Asset Management Inc owned 0.06% of USANA Health Sciences worth $520,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. raised its stake in shares of USANA Health Sciences by 4.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 222,423 shares of the company’s stock valued at $11,922,000 after buying an additional 8,536 shares in the last quarter. Dimensional Fund Advisors LP raised its position in USANA Health Sciences by 3.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 677,664 shares of the company’s stock worth $36,323,000 after purchasing an additional 21,524 shares in the last quarter. Trexquant Investment LP bought a new position in USANA Health Sciences during the fourth quarter worth about $266,000. Quest Partners LLC acquired a new stake in USANA Health Sciences during the fourth quarter valued at approximately $66,000. Finally, Allianz Asset Management GmbH grew its stake in shares of USANA Health Sciences by 43.0% in the 4th quarter. Allianz Asset Management GmbH now owns 26,970 shares of the company’s stock valued at $1,446,000 after purchasing an additional 8,108 shares during the period. 54.25% of the stock is owned by institutional investors.

Insider Activity at USANA Health Sciences

In other USANA Health Sciences news, insider Paul A. Jones sold 6,266 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total transaction of $240,489.08. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, Director John Turman Fleming sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total value of $44,430.00. Following the transaction, the director now owns 2,503 shares in the company, valued at $111,208.29. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Paul A. Jones sold 6,266 shares of USANA Health Sciences stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total value of $240,489.08. The disclosure for this sale can be found here. Insiders sold 7,940 shares of company stock valued at $311,670 over the last ninety days. 0.33% of the stock is owned by insiders.

USANA Health Sciences Trading Up 0.9 %

NYSE USNA opened at $38.42 on Monday. USANA Health Sciences, Inc. has a 1-year low of $36.05 and a 1-year high of $60.99. The company has a 50 day moving average of $41.37 and a 200-day moving average of $44.71. The firm has a market cap of $731.90 million, a price-to-earnings ratio of 11.97, a PEG ratio of 1.27 and a beta of 0.90.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings results on Tuesday, July 23rd. The company reported $0.54 earnings per share for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.11). The business had revenue of $212.87 million for the quarter, compared to analyst estimates of $218.64 million. USANA Health Sciences had a net margin of 6.29% and a return on equity of 11.13%. During the same period in the prior year, the business earned $0.89 earnings per share. On average, analysts forecast that USANA Health Sciences, Inc. will post 2.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. StockNews.com downgraded USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th. DA Davidson reduced their target price on shares of USANA Health Sciences from $46.00 to $38.00 and set a “neutral” rating on the stock in a research note on Thursday, July 25th.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.